Syngene International Limited

Mirae Asset Mutual Fund decreased its stake in Syngene International Limited from 1.85% to 1.05%, selling 31,95,263 shares.

India's first Contract Research Organization, Syngene provides integrated drug discovery, development, and manufacturing services through a single platform known as CRAMS. Established in 1993 as a Biocon subsidiary, the company operates extensive research and manufacturing facilities spanning multiple locations across the country. It serves global pharmaceutical and biotechnology clients with end-to-end solutions, from early-stage research through commercial-scale production.

Indian arm of South Korea's Mirae Asset Global Investments, one of Asia's largest asset managers. Manages over Rs 2.5 lakh crore in India across equity and hybrid funds. CIO Neelesh Surana has built a reputation for rigorous bottom-up stock selection with a long-term quality growth bias. Mirae Asset Emerging Bluechip Fund built a cult following before being closed to fresh investments due to size.